| scholarly article | Q13442814 |
| P2093 | author name string | Kathlynn C Brown | |
| Chin-Ying Chung | |||
| Benjamin J Umlauf | |||
| P2860 | cites work | Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes | Q24676216 |
| Intersection of autophagy with pathways of antigen presentation | Q26820833 | ||
| A liposomal drug platform overrides peptide ligand targeting to a cancer biomarker, irrespective of ligand affinity or density | Q27308658 | ||
| Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma | Q27860650 | ||
| Autophagy: from phenomenology to molecular understanding in less than a decade | Q29614174 | ||
| The role of autophagy in neurodegenerative disease | Q29614834 | ||
| Cancer immunotherapy comes of age | Q29619918 | ||
| sIR: siRNA Information Resource, a web-based tool for siRNA sequence design and analysis and an open access siRNA database | Q30483481 | ||
| Identification of a novel lysosomal trafficking peptide using phage display biopanning coupled with endocytic selection pressure | Q34343508 | ||
| Membrane traffic exploited by protein toxins | Q34762458 | ||
| Identification and characterization of a suite of tumor targeting peptides for non-small cell lung cancer | Q35131992 | ||
| Immune microenvironments in solid tumors: new targets for therapy | Q35642044 | ||
| Pathways followed by protein toxins into cells | Q35776193 | ||
| Antibody-recruiting molecules: an emerging paradigm for engaging immune function in treating human disease | Q36108119 | ||
| Melanoma prevention using topical PBISe | Q36384802 | ||
| Mass spectrometry and peptide-based vaccine development | Q36986531 | ||
| Drug delivery in cancer using liposomes | Q37120461 | ||
| Autophagy and its role in MHC-mediated antigen presentation | Q37315630 | ||
| Shiga toxins--from cell biology to biomedical applications | Q37659792 | ||
| Anticancer nanomedicine and tumor vascular permeability; Where is the missing link? | Q38026626 | ||
| Armed therapeutic viruses - a disruptive therapy on the horizon of cancer immunotherapy | Q38194135 | ||
| Oncolytic viruses and their application to cancer immunotherapy | Q38207011 | ||
| Effect of tumor cells and tumor microenvironment on NK-cell function. | Q38207947 | ||
| Peptide selection for presentation by HLA class I: a role for the human transporter associated with antigen processing? | Q41298877 | ||
| DNA typing for HLA class I alleles: I. Subsets of HLA-A2 and of -A28 | Q42611978 | ||
| Liposome-based vaccines | Q42994093 | ||
| Folate targeting of haptens to cancer cell surfaces mediates immunotherapy of syngeneic murine tumors | Q43952723 | ||
| Measles virus vaccine-infected tumor cells induce tumor antigen cross-presentation by human plasmacytoid dendritic cells | Q45110054 | ||
| Detection of vaccinia virus-specific IFNγ and IL-10 secretion from human PBMCs and CD8⁺ T cells by ELISPOT. | Q45362941 | ||
| Hemagglutinin protein is a primary target of the measles virus-specific HLA-A2-restricted CD8+ T cell response during measles and after vaccination | Q45404238 | ||
| Vaccination coverage among children in kindergarten--United States, 2011-12 school year. | Q50917799 | ||
| The B Subunit of Shiga Toxin Fused to a Tumor Antigen Elicits CTL and Targets Dendritic Cells to Allow MHC Class I-Restricted Presentation of Peptides Derived from Exogenous Antigens | Q56966367 | ||
| Major histocompatibility complex class I presentation of exogenous soluble tumor antigen fused to the B-fragment of Shiga toxin | Q56966504 | ||
| Exploiting retrograde transport of Shiga-like toxin 1 for the delivery of exogenous antigens into the MHC class I presentation pathway | Q60311719 | ||
| P433 | issue | 6 | |
| P304 | page(s) | 1092-1102 | |
| P577 | publication date | 2015-03-19 | |
| P1433 | published in | Molecular Therapy | Q15762400 |
| P1476 | title | Modular Three-component Delivery System Facilitates HLA Class I Antigen Presentation and CD8(+) T-cell Activation Against Tumors. | |
| P478 | volume | 23 |
Search more.